India to Turkey Pharmaceutical Export

The pharmaceutical trade between India and Turkey has experienced significant growth over the past decade. In 2024, India's pharmaceutical exports to Turkey reached $98.39 million, marking a substantial increase from previous years. This upward trajectory underscores the strengthening economic ties and the growing demand for Indian pharmaceutical products in the Turkish market.

Key milestones in this bilateral trade include the establishment of direct shipping routes and the initiation of joint ventures between Indian pharmaceutical companies and Turkish distributors. These collaborations have facilitated smoother logistics and enhanced market penetration. The consistent growth in export value reflects the successful adaptation of Indian pharmaceutical firms to the regulatory and market dynamics of Turkey.

India holds a significant share in Turkey's pharmaceutical import market, positioning itself as a key supplier alongside other origins. The strategic importance of this relationship is evident in the diversification of India's export portfolio, which includes a range of generic and branded formulations tailored to meet Turkey's healthcare needs. This market presence is bolstered by India's competitive pricing and the high quality of its pharmaceutical products.

Between 2024 and 2026, several developments have influenced the India-Turkey pharmaceutical trade. Notably, in December 2023, the Turkish Medicines and Medical Devices Agency published guidelines on the conditions for pharmaceutical exports by companies other than pharmaceutical warehouses. These guidelines aim to ensure that pharmaceutical products are exported in compliance with national and international standards, emphasizing the importance of Good Distribution Practices.

Additionally, in June 2022, Turkey announced the Regulation on Pharmaceutical Establishments and Products in Pharmaceutical Establishments, harmonizing the supply chain rules with European Union regulations. This regulation mandates that pharmaceutical products and active substances follow the legal supply chain, impacting the import and export processes.

EXPORT_REGULATORY

Indian pharmaceutical companies seeking to register products in Turkey must adhere to the guidelines set by the Turkish Medicines and Medical Devices Agency. The registration process involves submitting a comprehensive dossier that includes toxicological and pharmacological tests, clinical trial data, and a description of control methods used by the manufacturer. The dossier must be prepared in the Common Technical Document (CTD) format, which is internationally recognized. The timeline for registration can vary, but it typically spans several months, depending on the complexity of the product and the completeness of the submitted documentation.

Turkey requires that manufacturing sites comply with Good Manufacturing Practices (GMP) standards to ensure the quality and safety of pharmaceutical products. The inspection process involves a thorough evaluation of the manufacturing facilities, including assessments of production processes, quality control measures, and documentation practices. Mutual recognition agreements between Turkey and other countries may facilitate the acceptance of GMP certifications, but Indian manufacturers should verify the specific requirements and agreements in place to streamline the approval process.

To import pharmaceutical products into Turkey, companies must obtain an import license from the Ministry of Health. This license is granted based on a market authorization, which is typically held by the Turkish subsidiary of the pharmaceutical manufacturer. The import documentation includes a commercial invoice, bill of lading or airway bill, packing list, certificate of origin, and a certificate of analysis. Additionally, a certificate of control from the Ministry of Health is required, which involves submitting documents such as a pro forma invoice, certificate of analysis, and an approved health certificate issued by the competent authority in the country of origin.

EXPORT_TRENDS

The dominant categories in India's pharmaceutical exports to Turkey include antibiotics, vaccines, and oncology drugs. These therapeutic areas align with Turkey's healthcare needs, addressing prevalent infectious diseases, vaccination programs, and cancer treatment requirements. The demand for these products is driven by Turkey's efforts to enhance its healthcare infrastructure and provide comprehensive medical care to its population.

Emerging opportunities for Indian exporters in Turkey include the growing demand for biosimilars and the potential for collaboration in new therapeutic areas such as immunology and gene therapy. The Turkish government's focus on expanding healthcare access and improving treatment outcomes presents avenues for Indian pharmaceutical companies to introduce innovative products and technologies. Additionally, the expiration of patents for certain branded drugs opens the market for generic alternatives, providing a competitive edge for Indian manufacturers.

Turkey's increasing disease burden, aging population, and rising healthcare spending are primary drivers of import demand from India. The country's efforts to modernize its healthcare system and provide quality medical services to its citizens contribute to the growing need for pharmaceutical imports. Additionally, Turkey's strategic location as a bridge between Europe and Asia enhances its role as a significant market for pharmaceutical products.

EXPORT_POLICY

Turkey's Most Favored Nation (MFN) tariff rates for pharmaceutical formulations are generally low, reflecting the country's commitment to ensuring affordable access to essential medicines. Preferential rates and duty exemptions may apply under specific trade agreements or for products that meet certain criteria, such as those addressing public health priorities. Indian pharmaceutical exporters should consult the latest Turkish customs regulations and trade agreements to determine applicable tariffs and potential exemptions.

Turkey and India have engaged in discussions to enhance bilateral trade relations, including the pharmaceutical sector. While there is no comprehensive Free Trade Agreement (FTA) in place, both countries have expressed interest in reducing trade barriers and facilitating smoother market access. Ongoing negotiations aim to address issues such as intellectual property rights, regulatory harmonization, and customs procedures to promote mutual trade interests.

Turkey's intellectual property laws, including those related to patents and data exclusivity, impact the entry of Indian generic drugs into the Turkish market. The country adheres to international agreements such as the Trade-Related Aspects of Intellectual Property Rights (TRIPS), which influences patent protection and enforcement. Indian exporters must navigate these regulations to ensure compliance and to identify opportunities for market entry, especially in the generic segment.

EXPORT_LOGISTICS

Major sea and air routes facilitate the transportation of pharmaceutical products from Indian ports to Turkey. Sea routes typically involve transit through the Suez Canal, with an estimated transit time of 15-20 days, depending on the specific ports of departure and arrival. Air routes offer faster delivery, with transit times ranging from 5 to 7 days. However, geopolitical events, such as tensions in the Red Sea region, can disrupt these routes, potentially affecting delivery schedules. Exporters should monitor geopolitical developments and plan logistics accordingly to mitigate potential disruptions.

In India, key export ports include Sahar Air Cargo (INBOM4) and Sahar Air, which handle a significant portion of pharmaceutical exports. In Turkey, major import ports are Istanbul and Mersin, which serve as primary entry points for pharmaceutical products. The choice of port can influence shipping times and costs, and exporters should coordinate with logistics partners to optimize the supply chain.

Maintaining the integrity of pharmaceutical products during transit is critical, especially for temperature-sensitive items. Compliance with Good Distribution Practices (GDP) and adherence to packaging standards are essential to ensure product quality upon arrival. Indian exporters should collaborate with logistics providers experienced in pharmaceutical shipments to implement effective cold chain solutions and ensure compliance with both Indian and Turkish regulations.

EXPORT_OPPORTUNITY

Turkey's pharmaceutical market is substantial, with a sales value of 211 billion Turkish lira in 2023. The market has shown continuous growth, with the medicinal products segment totaling 13 billion Turkish lira in 2023. This growth presents significant opportunities for Indian pharmaceutical exporters to expand their market share and introduce a diverse range of products.

Turkey's healthcare system is undergoing modernization, with increased government spending and efforts to improve access to medical services. The introduction of universal health coverage and the expansion of healthcare infrastructure contribute to a growing demand for pharmaceutical products. These developments create a favorable environment for Indian exporters to establish partnerships and supply essential medicines to the Turkish market.

Specific opportunities for Indian exporters include supplying generic versions of high-demand branded drugs, offering cost-effective alternatives in therapeutic areas such as oncology and cardiology, and collaborating on the development of biosimilars. The growth outlook for Indian pharmaceutical companies in Turkey is positive, driven by the country's expanding healthcare needs and the established reputation of Indian products for quality and affordability.

EXPORT_COMPETITIVE